FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

William Plunkett

Research Profile

Chemicals & Drugs

Disorders

Procedures

Antineoplastic Combined Chemotherapy Protocols

Anatomy

Tumor Cells, Cultured

Concepts & Ideas

Co-author Network

Publications

TOP 3
Hagop Kantarjian; Selina Luger; Lori Maness; Gary Schiller; Karen Seiter; Wendy Stock; Stephen A Strickland; Parameswaran Venugopal; Meir Wetzler; Martha Arellano; Judy Chiao; David Claxton; Steven Coutre; Stefan Faderl; Guillermo Garcia-Manero; Stuart L Goldberg; Elias Jabbour; William Plunkett
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
Xiao-Jun Liu; Billie Nowak; Ya-Qing Wang; William Plunkett
Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Elias Jabbour; Tapan Kadia; Marina Konopleva; Susan O'Brien; William Plunkett; Farhad Ravandi; Gautam Borthakur; Mark Brandt; Jan Burger; Jorge Cortes; Stefan Faderl; Varsha Gandhi; Guillermo Garcia-Manero; Xuelin Huang; Hagop Kantarjian
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of William Plunkett (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Hagop Kantarjian; Selina Luger; Lori Maness; Gary Schiller; Karen Seiter; Wendy Stock; Stephen A Strickland; Parameswaran Venugopal; Meir Wetzler; Martha Arellano; Judy Chiao; David Claxton; Steven Coutre; Stefan Faderl; Guillermo Garcia-Manero; Stuart L Goldberg; Elias Jabbour; William Plunkett
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
The lancet oncology 2012;13(11):1096-104.
2012: Xiao-Jun Liu; Billie Nowak; Ya-Qing Wang; William Plunkett
Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Chinese journal of cancer 2012;31(8):373-80.
2012: Elias Jabbour; Tapan Kadia; Marina Konopleva; Susan O'Brien; William Plunkett; Farhad Ravandi; Gautam Borthakur; Mark Brandt; Jan Burger; Jorge Cortes; Stefan Faderl; Varsha Gandhi; Guillermo Garcia-Manero; Xuelin Huang; Hagop Kantarjian
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Clinical lymphoma, myeloma & leukemia 2012;12(4):244-51.
2012: Xiaojun Liu; Hagop Kantarjian; William Plunkett
Sapacitabine for cancer.
Expert opinion on investigational drugs 2012;21(4):541-55.
2011: Alma Zecevic; Rong Chen; Brett Ewald; Deepa Sampath; William G Wierda; William Plunkett
Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(14):4731-41.
2011: Rong Chen; Lei Guo; Yuling Chen; Yingjun Jiang; William G Wierda; William Plunkett
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.
Blood 2011;117(1):156-64.
2010: Wen-Wei Tsai; Zhanxin Wang; Teresa T Yiu; Kadir C Akdemir; Weiya Xia; Stefan Winter; Cheng-Yu Tsai; Xiaobing Shi; Dirk Schwarzer; William Plunkett; Bruce Aronow; Or Gozani; Wolfgang Fischle; Mien-Chie Hung; Dinshaw J Patel; Michelle Craig Barton
TRIM24 links a non-canonical histone signature to breast cancer.
Nature 2010;468(7326):927-32.
2010: Xiaojun Liu; Yaqing Wang; Sherri Benaissa; Akira Matsuda; Andrew Lamb; Zeev Estrov; William Plunkett
Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.
Blood 2010;116(10):1737-46.
2010: Simona Rossi; Masayoshi Shimizu; Elisa Barbarotto; Milena S Nicoloso; Federica Dimitri; Deepa Sampath; Muller Fabbri; Susan Lerner; Lynn L Barron; Laura Rassenti; Li Jiang; Lianchun Xiao; Jianhua Hu; Paola Secchiero; Giorgio Zauli; Stefano Volinia; Massimo Negrini; William G Wierda; Thomas J Kipps; William Plunkett; Kevin R Coombes; Lynne V Abruzzo; Michael J Keating; George A Calin
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.
Blood 2010;116(6):945-52.
2010: Wei-Gang Tong; Rong Chen; William Plunkett; David Siegel; Rajni Sinha; R Donald Harvey; Ashraf Badros; Leslie Popplewell; Steven Coutre; Judith A Fox; Kristi Mahadocon; Tianling Chen; Peggy Kegley; Ute Hoch; William G Wierda
Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(18):3015-22.
2010: Stefan Faderl; Guillermo Garcia-Manero; Zeev Estrov; Farhad Ravandi; Gautam Borthakur; Jorge E Cortes; Susan O'Brien; Varsha Gandhi; William Plunkett; Anna Byrd; Monica Kwari; Hagop M Kantarjian
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(16):2755-60.
2010: Rong Chen; William Plunkett
Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia.
Best practice & research. Clinical haematology 2010;23(1):155-66.
2010: Andrew Lamb; Guillermo Garcia-Manero; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Robert Westwood; Simon R Green; Judy H Chiao; Patricia A Boone; Jorge Cortes; William Plunkett
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(2):285-91.
2009: Stanley Pounds; Cheng Cheng; Xueyuan Cao; Kristine R Crews; William Plunkett; Varsha Gandhi; Jeffrey E Rubnitz; Raul C Ribeiro; James R Downing; Jatinder Lamba
PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables.
Bioinformatics (Oxford, England) 2009;25(16):2013-9.
2009: Rong Chen; William G Wierda; Sherri Chubb; Rachael E Hawtin; Judith A Fox; Michael J Keating; Varsha Gandhi; William Plunkett
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Blood 2009;113(19):4637-45.
2009: Deepa Sampath; George A Calin; Vinay K Puduvalli; Gopal Gopisetty; Cristian Taccioli; Chang-gong liu; Brett Ewald; Chaomei Liu; Michael J Keating; William Plunkett
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation.
Blood 2009;113(16):3744-53.
2008: Gautam Borthakur; Andrew Lamb; Xuemei Wang; William Plunkett; Varsha Gandhi; Stefan Faderl; Guillermo Garcia-Manero; Farhad Ravandi; Sherry Pierce; Elihu H Estey
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Cancer 2008;113(11):3181-5.
2008: B Ewald; Deepa Sampath; William Plunkett
Nucleoside analogs: molecular mechanisms signaling cell death.
Oncogene 2008;27(50):6522-37.
2008: Brett Ewald; Deepa Sampath; William Plunkett
ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance.
Cancer research 2008;68(19):7947-55.
2008: Lisa S Chen; William Plunkett; Varsha Gandhi
Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues.
Leukemia research 2008;32(10):1573-81.
2008: Dunyaporn Trachootham; Hui Zhang; Wan Zhang; Li Feng; Min Du; Yan Zhou; Zhao Chen; Helene Pelicano; William Plunkett; William G Wierda; Michael J Keating; Peng Huang
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
Blood 2008;112(5):1912-22.
2008: Yaqing Wang; Xiaojun Liu; Akira Matsuda; William Plunkett
Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair.
Cancer research 2008;68(10):3881-9.
2008: Varsha Gandhi; Constantine Tam; Susan O'Brien; Roxanne C Jewell; Carlos O Rodriguez; Susan Lerner; William Plunkett; Michael J Keating
Phase I trial of nelarabine in indolent leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1098-105.
2008: Apostolia-Maria Tsimberidou; William G Wierda; William Plunkett; Razelle Kurzrock; Susan O'Brien; Sijin Wen; Alessandra Ferrajoli; Farhad Ravandi-Kashani; Guillermo Garcia-Manero; Zeev Estrov; Thomas Kipps; Jennifer R Brown; Albert Fiorentino; Susan Lerner; Hagop M Kantarjian; Michael J Keating
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):196-203.
2008: Xiaojun Liu; Akira Matsuda; William Plunkett
Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine.
Molecular cancer therapeutics 2008;7(1):133-42.
2007: Esmerina Tili; Jean-Jacques Michaille; Varsha Gandhi; William Plunkett; Deepa Sampath; George A Calin
miRNAs and their potential for use against cancer and other diseases.
Future oncology (London, England) 2007;3(5):521-37.
2007: Lei Guo; Xiaojun Liu; Kiyohiro Nishikawa; William Plunkett
Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
Molecular cancer therapeutics 2007;6(5):1501-8.
2007: Brett Ewald; Deepa Sampath; William Plunkett
H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation.
Molecular cancer therapeutics 2007;6(4):1239-48.
2006: Helene Pelicano; Rui-Hua Xu; Min Du; Li Feng; Ryohei Sasaki; Jennifer Carew; Yumin Hu; Latha Ramdas; Limei Hu; Michael J Keating; Wei Zhang; William Plunkett; Peng Huang
Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism.
The Journal of cell biology 2006;175(6):913-23.
2006: Mazin A Moufarij; Deepa Sampath; Michael J Keating; William Plunkett
Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
Blood 2006;108(13):4187-93.
2006: Rong Chen; Varsha Gandhi; William Plunkett
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
Cancer research 2006;66(22):10959-66.
2006: Varsha Gandhi; William Plunkett
Clofarabine and nelarabine: two new purine nucleoside analogs.
Current opinion in oncology 2006;18(6):584-90.
2006: Kensuke Kojima; Marina Konopleva; Teresa McQueen; Susan O'Brien; William Plunkett; Michael Andreeff
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Blood 2006;108(3):993-1000.
2006: Varsha Gandhi; William Plunkett; Peter L Bonate; Min Du; Billie Nowak; Susan Lerner; Michael J Keating
Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(13):4011-7.
2006: Helene Pelicano; Jennifer Carew; Teresa McQueen; Michael Andreeff; William Plunkett; Michael J Keating; P Huang
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
Leukemia 2006;20(4):610-9.
2006: Deepa Sampath; Jorge Cortes; Zeev Estrov; Min Du; Zheng Shi; Michael Andreeff; Varsha Gandhi; William Plunkett
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.
Blood 2006;107(6):2517-24.
2006: Andrew Lamb; Miloslav Beran; Jorge Cortes; Susan O'Brien; Francis Giles; Sherry Pierce; Jianqin Shan; William Plunkett; Michael Keating; Elihu Estey
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Cancer 2006;106(5):1099-109.
2005: Varsha Gandhi; J Michael Kilpatrick; William Plunkett; Mary Ayres; Leigh Harman; Min Du; Shanta Bantia; Jan Davisson; William G Wierda; Stefan Faderl; Andrew Lamb; Deborah Thomas
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Blood 2005;106(13):4253-60.
2005: Rong Chen; Michael J Keating; Varsha Gandhi; William Plunkett
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
Blood 2005;106(7):2513-9.
2005: Xiaojun Liu; Ying Guo; Yexiong Li; Yingjun Jiang; Sherri Chubb; Atsushi Azuma; Peng Huang; Akira Matsuda; Walter N Hittelman; William Plunkett
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Cancer research 2005;65(15):6874-81.
2005: Elias Jabbour; Srdan Verstovsek; Francis Giles; Varsha Gandhi; Jorge Cortes; Susan O'Brien; William Plunkett; Guillermo Garcia-Manero; C Ellen Jackson; Andrew Lamb; Michael Andreeff
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
Cancer 2005;104(3):541-6.
2005: Michael J Keating; Susan O'Brien; Maher Albitar; Susan Lerner; William Plunkett; Francis Giles; Michael Andreeff; Jorge Cortes; Stefan Faderl; Deborah Thomas; Charles Koller; William G Wierda; Michelle A Detry; Alice Lynn; Andrew Lamb
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4079-88.
2005: Henry Q Xiong; William Plunkett; Robert Wolff; Min Du; Renato Lenzi; James L Abbruzzese
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.
Cancer chemotherapy and pharmacology 2005;55(6):559-64.
2005: Stefan Faderl; Varsha Gandhi; Michael J Keating; Sima Jeha; William Plunkett; Hagop M Kantarjian
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
Cancer 2005;103(10):1985-95.
2005: Stefan Faderl; Varsha Gandhi; Susan O'Brien; Peter L Bonate; Jorge Cortes; Elihu Estey; Miloslav Beran; William G Wierda; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Francis Giles; Min Du; Monica Kwari; Michael Keating; William Plunkett; Andrew Lamb
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Blood 2005;105(3):940-7.
2004: Peter L Bonate; Adam Craig; Paul S Gaynon; Varsha Gandhi; Sima Jeha; Richard Kadota; Gilbert N Lam; William Plunkett; Bassem I Razzouk; Michael Rytting; Peter G Steinherz; Steven D Weitman
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia.
Journal of clinical pharmacology 2004;44(11):1309-22.
2004: Sima Jeha; Varsha Gandhi; Ka Wah Chan; Lisa McDonald; Irma Ramirez; Renee Madden; Michael Rytting; Mark Brandt; Michael Keating; William Plunkett; Andrew Lamb
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.
Blood 2004;103(3):784-9.
2003: Varsha Gandhi; Andrew Lamb; Stefan Faderl; Peter L Bonate; Min Du; Mary Ayres; Mary Beth Rios; Michael J Keating; William Plunkett
Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(17):6335-42.
2003: Deepa Sampath; V Ashutosh Rao; William Plunkett
Mechanisms of apoptosis induction by nucleoside analogs.
Oncogene 2003;22(56):9063-74.
2003: Francis Giles; Paula M Fracasso; Hagop M Kantarjian; Jorge E Cortes; Randy A Brown; Srdan Verstovsek; Yesid Alvarado; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Lisa P Wright; Tom Samson; Ann Cahill; Paula Lambert; William Plunkett; Mario Sznol; John F DiPersio; Varsha Gandhi
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Leukemia research 2003;27(12):1077-83.
2003: Helene Pelicano; Li Feng; Yan Zhou; Jennifer Carew; Elizabeth O Hileman; William Plunkett; Michael J Keating; Peng Huang
Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism.
The Journal of biological chemistry 2003;278(39):37832-9.
2003: Li-Ying Yang; Hong Jiang; Kelly M Rangel; William Plunkett
Cisplatin-induced ubiquitination of RNA polymerase II large subunit and suppression of induction by 7-hydroxystaurosporine (UCN-01).
Oncology reports 2003;10(5):1489-95.
2003: V Ashutosh Rao; William Plunkett
Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(8):3204-12.
2003: Yan Zhou; Elizabeth O Hileman; William Plunkett; Michael J Keating; Peng Huang
Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents.
Blood 2003;101(10):4098-104.
2003: Hagop M Kantarjian; Varsha Gandhi; Peter Kozuch; Stefan Faderl; Francis Giles; Jorge Cortes; Susan O'Brien; Nuhad Ibrahim; Fadlo R Khuri; Min Du; Mary Beth Rios; Sima Jeha; Peter McLaughlin; William Plunkett; Michael Keating
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1167-73.
2002: Michael J Keating; Susan O'Brien; Dimitrios P Kontoyiannis; William Plunkett; Charles Koller; Miloslav Beran; Susan Lerner; Andrew Lamb
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.
Leukemia & lymphoma 2002;43(9):1755-62.
2002: Deepa Sampath; Zheng Shi; William Plunkett
Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine.
Molecular pharmacology 2002;62(3):680-8.
2002: Takahiro Yamauchi; Michael J Keating; William Plunkett
UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes.
Molecular cancer therapeutics 2002;1(4):287-94.
2002: Varsha Gandhi; William Plunkett; Min Du; Mary Ayres; Elihu H Estey
Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):665-73.
2002: Stefan Faderl; Varsha Gandhi; Andrew Lamb; William Plunkett
New nucleoside analogues in clinical development.
Cancer chemotherapy and biological response modifiers 2002;20():37-58.
2002: Varsha Gandhi; William Plunkett
Cellular and clinical pharmacology of fludarabine.
Clinical pharmacokinetics 2002;41(2):93-103.
2002: Yan Zhou; Geetha Achanta; Helene Pelicano; Varsha Gandhi; William Plunkett; Peng Huang
Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response.
Molecular pharmacology 2002;61(1):222-9.
2001: Geetha Achanta; Helene Pelicano; Lei Feng; William Plunkett; P Huang
Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage.
Cancer research 2001;61(24):8723-9.
2001: T Yamauchi; B J Nowak; Michael J Keating; William Plunkett
DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(11):3580-9.
2001: Deepa Sampath; William Plunkett
Design of new anticancer therapies targeting cell cycle checkpoint pathways.
Current opinion in oncology 2001;13(6):484-90.
2001: Shreyaskumar R Patel; Varsha Gandhi; Jan Jenkins; Nicholas Papadopolous; Michael A Burgess; Carl Plager; William Plunkett; Robert S Benjamin
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(15):3483-9.
2001: Randall E Millikan; William Plunkett; Terry L Smith; D L Williams; Christopher J Logothetis
Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin.
Cancer 2001;92(1):194-9.
2001: Atsushi Azuma; P Huang; Akira Matsuda; William Plunkett
Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC).
Biochemical pharmacology 2001;61(12):1497-507.
2001: Varsha Gandhi; William Plunkett; S Weller; Min Du; Mary Ayres; Carlos O Rodriguez; P Ramakrishna; Gary Rosner; JP Hodge; Susan O'Brien; Michael J Keating
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2142-52.
2001: Atsushi Azuma; P Huang; Akira Matsuda; William Plunkett
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
Molecular pharmacology 2001;59(4):725-31.
2001: Zheng Shi; Atsushi Azuma; Deepa Sampath; Y X Li; P Huang; William Plunkett
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine.
Cancer research 2001;61(3):1065-72.
2001: William Plunkett; Varsha Gandhi
Purine and pyrimidine nucleoside analogs.
Cancer chemotherapy and biological response modifiers 2001;19():21-45.
2000: Deepa Sampath; William Plunkett
The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage.
Cancer research 2000;60(22):6408-15.
2000: P Huang; Li Feng; E A Oldham; Michael J Keating; William Plunkett
Superoxide dismutase as a target for the selective killing of cancer cells.
Nature 2000;407(6802):390-5.
2000: Carlos O Rodriguez; William Plunkett; M T Paff; Min Du; B Nowak; P Ramakrishna; Michael J Keating; Varsha Gandhi
High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells.
Journal of chromatography. B, Biomedical sciences and applications 2000;745(2):421-30.
2000: P Huang; A Sandoval; E Van Den Neste; Michael J Keating; William Plunkett
Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
Leukemia 2000;14(8):1405-13.
2000: Lei Feng; Geetha Achanta; Helene Pelicano; Wei Zhang; William Plunkett; P Huang
Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage.
International journal of molecular medicine 2000;5(6):597-604.
2000: Li-Ying Yang; Li Li; Hong Jiang; Yu Shen; William Plunkett
Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):773-81.
2000: David Kisor; William Plunkett; Joanne Kurtzberg; Beverly S Mitchell; JP Hodge; T Ernst; Michael J Keating; Varsha Gandhi
Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(5):995-1003.
2000: Francisco J Esteva; L T Soh; Frankie A Holmes; William Plunkett; Christina A Meyers; Arthur Forman; Gabriel N Hortobagyi
Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.
Cancer chemotherapy and pharmacology 2000;46(5):382-6.
1999: Francis Giles; Susan M O'Brien; V Santini; Varsha Gandhi; William Plunkett; John F Seymour; LE Robertson; Hagop M Kantarjian; Michael J Keating
Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
Leukemia & lymphoma 1999;36(1-2):57-65.
1999: Alvaro Aguayo; Jorge E Cortes; Hagop M Kantarjian; Miloslav Beran; Varsha Gandhi; William Plunkett; Joanne Kurtzberg; Michael J Keating
Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.
Cancer 1999;85(1):58-64.
1999: Luka Milas; T Fujii; Nancy Hunter; Mohamed A Elshaikh; Kathy Mason; William Plunkett; K. Kian Ang; Walter N Hittelman
Enhancement of tumor radioresponse in vivo by gemcitabine.
Cancer research 1999;59(1):107-14.
1998: Varsha Gandhi; William Plunkett; Carlos O Rodriguez; B J Nowak; Min Du; Mary Ayres; David Kisor; Beverly S Mitchell; Joanne Kurtzberg; Michael J Keating
Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(11):3607-15.
1998: Varsha Gandhi; William Plunkett; Andrew Lamb; Moshe Talpaz; LE Robertson; Susan O'Brien
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2321-31.
1998: U Consoli; I El-Tounsi; A Sandoval; Virginia Snell; H D Kleine; W Brown; J R Robinson; F DiRaimondo; William Plunkett; Michael Andreeff
Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia.
Blood 1998;91(5):1742-8.
1997: Li Li; Michael J Keating; William Plunkett; Li-Ying Yang
Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Molecular pharmacology 1997;52(5):798-806.
1997: Varsha Gandhi; Elihu Estey; Min Du; Michael J Keating; William Plunkett
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(9):1539-45.
1997: P Huang; K Ballal; William Plunkett
Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis.
Cancer research 1997;57(16):3407-14.
1997: Varsha Gandhi; P Huang; A J Chapman; F Chen; William Plunkett
Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(8):1347-55.
1997: H Iwasaki; P Huang; Michael J Keating; William Plunkett
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
Blood 1997;90(1):270-8.
1997: Li Li; Xiaojun Liu; Armand B. Glassman; Michael J Keating; M Stros; William Plunkett; Li-Ying Yang
Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro.
Cancer research 1997;57(8):1487-94.
1996: Michael J Keating; Susan O'Brien; Peter McLaughlin; Meletios A Dimopoulos; Varsha Gandhi; William Plunkett; Susan Lerner; Andrew Lamb; Elihu Estey
Clinical experience with fludarabine in hemato-oncology.
Hematology and cell therapy 1996;38 Suppl 2():S83-91.
1996: William Plunkett; Varsha Gandhi
Pharmacology of purine nucleoside analogues.
Hematology and cell therapy 1996;38 Suppl 2():S67-74.
1996: V Grégoire; Nancy Hunter; W A Brock; Walter N Hittelman; William Plunkett; Luka Milas
Improvement in the therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus fludarabine.
Radiation research 1996;146(5):548-53.
1996: A Sandoval; U Consoli; William Plunkett
Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1731-41.
1996: William Plunkett; A Begleiter; J O Liliemark; J C Reed
Why do drugs work in CLL?
Leukemia & lymphoma 1996;22 Suppl 2():1-11.
1996: William Plunkett; P Huang; C E Searcy; Varsha Gandhi
Gemcitabine: preclinical pharmacology and mechanisms of action.
Seminars in oncology 1996;23(5 Suppl 10):3-15.
1996: Steven M Kornblau; Varsha Gandhi; H M Andreeff; Miloslav Beran; Hagop M Kantarjian; Charles Koller; Susan O'Brien; William Plunkett; Elihu Estey
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Leukemia 1996;10(10):1563-9.
1996: Varsha Gandhi; J Legha; F Chen; L W Hertel; William Plunkett
Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA.
Cancer research 1996;56(19):4453-9.
1996: K Kamiya; P Huang; William Plunkett
Inhibition of the 3' --> 5' exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA.
The Journal of biological chemistry 1996;271(32):19428-35.
1996: Keping Xie; William Plunkett
Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine.
Cancer research 1996;56(13):3030-7.
1996: Varsha Gandhi; Elihu H Estey; Michael J Keating; William Plunkett
Intracellular pharmacodynamics in leukemia therapy.
[Rinshō ketsueki] The Japanese journal of clinical hematology 1996;37(5):369-79.
1996: J F Seymour; P Huang; William Plunkett; Varsha Gandhi
Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(4):653-8.
1996: David J McConkey; Joya Chandra; S Wright; William Plunkett; Timothy J McDonnell; J C Reed; Michael Keating
Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(7):2624-30.
1996: LE Robertson; William Plunkett; K McConnell; Michael J Keating; Timothy J McDonnell
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome.
Leukemia 1996;10(3):456-9.
1996: SM Loughlin; Varsha Gandhi; William Plunkett; Leonard A Zwelling
The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
Cancer chemotherapy and pharmacology 1996;38(3):261-8.
1996: LE Robertson; A W Denny; Y O Huh; William Plunkett; Michael J Keating; J Arly Nelson
Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.
Cancer chemotherapy and pharmacology 1996;37(5):445-50.
1996: Varsha Gandhi; Elihu Estey; Michael J Keating; A Chucrallah; William Plunkett
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
Blood 1996;87(1):256-64.
1995: J A Benvenuto; Walter N Hittelman; Leonard A Zwelling; William Plunkett; Tej K Pandita; David Farquhar; Robert A Newman
Biochemical pharmacology of penclomedine (NSC-338720).
Biochemical pharmacology 1995;50(8):1157-64.
1995: P Huang; LE Robertson; S Wright; William Plunkett
High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(9):1005-13.
1995: LE Robertson; Susan O'Brien; Andrew Lamb; Charles Koller; Miloslav Beran; Michael Andreeff; Susan Lerner; William Plunkett; Michael J Keating
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
Leukemia 1995;9(9):1444-9.
1995: Varsha Gandhi; Shin Mineishi; P Huang; Y Yang; S Chubb; A J Chapman; B J Nowak; L W Hertel; William Plunkett
Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.
Seminars in oncology 1995;22(4 Suppl 11):61-7.
1995: William Plunkett; P Huang; Y Z Xu; V Heinemann; R Grunewald; Varsha Gandhi
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
Seminars in oncology 1995;22(4 Suppl 11):3-10.
1995: P Huang; William Plunkett
Induction of apoptosis by gemcitabine.
Seminars in oncology 1995;22(4 Suppl 11):19-25.
1995: V Grégoire; Arnout C Ruifrok; Roger E Price; W A Brock; Walter N Hittelman; William Plunkett; K. Kian Ang
Effect of intra-peritoneal fludarabine on rat spinal cord tolerance to fractionated irradiation.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1995;36(1):50-5.
1995: C Xie; William Plunkett
Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells.
Cancer research 1995;55(13):2847-52.
1995: Li-Ying Yang; Li Li; Michael J Keating; William Plunkett
Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
Molecular pharmacology 1995;47(5):1072-9.
1995: Varsha Gandhi; Shin Mineishi; P Huang; A J Chapman; Y Yang; F Chen; B Nowak; S Chubb; L W Hertel; William Plunkett
Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells.
Cancer research 1995;55(7):1517-24.
1995: Varsha Gandhi; Elihu Estey; Min Du; B Nowak; Michael J Keating; William Plunkett
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(2):169-78.
1995: Y Z Xu; P Huang; William Plunkett
Functional compartmentation of dCTP pools. Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts.
The Journal of biological chemistry 1995;270(2):631-7.
1995: P Huang; William Plunkett
Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event.
Cancer chemotherapy and pharmacology 1995;36(3):181-8.
1994: V Grégoire; NT Van; L Clifton Stephens; W A Brock; Luka Milas; William Plunkett; Walter N Hittelman
The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo.
Cancer research 1994;54(23):6201-9.
1994: V Grégoire; Nancy Hunter; W A Brock; Luka Milas; William Plunkett; Walter N Hittelman
Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single-dose irradiation.
International journal of radiation oncology, biology, physics 1994;30(2):363-71.
1994: Varsha Gandhi; Min Du; Hagop M Kantarjian; William Plunkett
Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia.
Leukemia 1994;8(9):1463-8.
1994: S J Wright; LE Robertson; Susan O'Brien; William Plunkett; Michael J Keating
The role of fludarabine in hematological malignancies.
Blood reviews 1994;8(3):125-34.
1994: H M Ghaddar; William Plunkett; Hagop M Kantarjian; Sherry Pierce; Emil J Freireich; Michael J Keating; Elihu H Estey
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Leukemia 1994;8(8):1269-74.
1994: S Lockhart; William Plunkett; Sima Jeha; I Ramirez; Theodore F Zipf; A Cork; D Pinkel
High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(3):587-95.
1994: V Grégoire; Nancy Hunter; Luka Milas; W A Brock; William Plunkett; Walter N Hittelman
Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine.
Cancer research 1994;54(2):468-74.
1994: Michael J Keating; Peter McLaughlin; William Plunkett; LE Robertson; Susan O'Brien; Varsha Gandhi; V Gregoire; L Yang; Fernando Cabanillas
Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 2():79-83.
1994: Varsha Gandhi; LE Robertson; Michael J Keating; William Plunkett
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
Cancer chemotherapy and pharmacology 1994;34(1):30-6.
1994: A L Ellis; B Nowak; William Plunkett; Leonard A Zwelling
Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Cancer chemotherapy and pharmacology 1994;34(3):249-56.
1994: Varsha Gandhi; P Huang; William Plunkett
Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias.
Leukemia & lymphoma 1994;14 Suppl 2():3-9.
1994: Varsha Gandhi; Elihu Estey; William Plunkett
Modulation of arabinosylcytosine metabolism during leukemia therapy.
Advances in experimental medicine and biology 1994;370():119-24.
1994: Michael J Keating; Elihu Estey; Susan O'Brien; Andrew Lamb; LE Robertson; William Plunkett
Clinical experience with fludarabine in leukaemia.
Drugs 1994;47 Suppl 6():39-49.
1994: William Plunkett; Varsha Gandhi
Evolution of the arabinosides and the pharmacology of fludarabine.
Drugs 1994;47 Suppl 6():30-8.
1994: Michael J Keating; Susan O'Brien; William Plunkett; LE Robertson; Varsha Gandhi; Elihu Estey; Meletios A Dimopoulos; Fernando Cabanillas; A Kemena; Andrew Lamb
Fludarabine phosphate: a new active agent in hematologic malignancies.
Seminars in hematology 1994;31(1):28-39.
1993: Y Z Xu; William Plunkett
Regulation of thymidine kinase and thymidylate synthase in intact human lymphoblast CCRF-CEM cells.
The Journal of biological chemistry 1993;268(30):22363-8.
1993: S Suki; Andrew Lamb; Varsha Gandhi; Elihu Estey; Susan O'Brien; Miloslav Beran; Mary Beth Rios; William Plunkett; Michael Keating
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
Cancer 1993;72(7):2155-60.
1993: William Plunkett; Varsha Gandhi; P Huang; LE Robertson; Li-Ying Yang; V Gregoire; Elihu Estey; Michael J Keating
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
Seminars in oncology 1993;20(5 Suppl 7):2-12.
1993: Michael J Keating; Susan O'Brien; Andrew Lamb; William Plunkett; Elihu Estey; Charles Koller; Miloslav Beran; Emil J Freireich
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
Blood 1993;81(11):2878-84.
1993: A Kemena; Susan O'Brien; Andrew Lamb; L Robertson; Charles Koller; Miloslav Beran; Elihu Estey; William Plunkett; Susan Lerner; Michael J Keating
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.
Leukemia & lymphoma 1993;10(3):187-93.
1993: Varsha Gandhi; A Kemena; Michael J Keating; William Plunkett
Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.
Leukemia & lymphoma 1993;10(1-2):49-56.
1993: LE Robertson; R Hall; Michael J Keating; Elihu Estey; Hagop M Kantarjian; Peter McLaughlin; F B Hagemeister; William Plunkett
High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis.
Leukemia & lymphoma 1993;10(1-2):43-8.
1993: Elihu Estey; William Plunkett; Varsha Gandhi; Mary Beth Rios; Andrew Lamb; Michael J Keating
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
Leukemia & lymphoma 1993;9(4-5):343-50.
1993: Hagop M Kantarjian; Miloslav Beran; A Ellis; Leonard A Zwelling; Susan O'Brien; L Cazenave; Charles Koller; Mary Beth Rios; William Plunkett; Michael J Keating
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Blood 1993;81(5):1146-51.
1993: William Plunkett; Varsha Gandhi
Cellular pharmacodynamics of anticancer drugs.
Seminars in oncology 1993;20(1):50-63.
1993: Elihu H Estey; William Plunkett; Andrew Lamb; Mary Beth Rios; Michael J Keating
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.
Leukemia & lymphoma 1993;10 Suppl():115-21.
1993: Varsha Gandhi; Elihu Estey; Michael J Keating; William Plunkett
Biochemical modulation of arabinosylcytosine for therapy of leukemias.
Leukemia & lymphoma 1993;10 Suppl():109-14.
1993: Varsha Gandhi; Elihu Estey; Michael J Keating; William Plunkett
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(1):116-24.
1993: LE Robertson; William Plunkett
Apoptotic cell death in chronic lymphocytic leukemia.
Leukemia & lymphoma 1993;11 Suppl 2():71-4.
1993: Michael J Keating; Susan O'Brien; L Robertson; Y Huh; Andrew Lamb; William Plunkett
Chronic lymphocytic leukemia--correlation of response and survival.
Leukemia & lymphoma 1993;11 Suppl 2():167-75.
1993: LE Robertson; S Chubb; Raymond E Meyn; M Story; R Ford; Walter N Hittelman; William Plunkett
Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine.
Blood 1993;81(1):143-50.
1992: P Huang; William Plunkett
A quantitative assay for fragmented DNA in apoptotic cells.
Analytical biochemistry 1992;207(1):163-7.
1992: Y Z Xu; William Plunkett
Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine.
Biochemical pharmacology 1992;44(9):1819-27.
1992: J R Redman; Fernando Cabanillas; W S Velasquez; Peter McLaughlin; F B Hagemeister; F Swan; Maria A Rodriguez; William Plunkett; Michael J Keating
Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):790-4.
1992: R Grunewald; Andrew Lamb; Min Du; K Faucher; P Tarassoff; William Plunkett
Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):406-13.
1992: J K Sastry; Pramod N Nehete; Saeed R Khan; B J Nowak; William Plunkett; Ralph B Arlinghaus; D Farquhar
Membrane-permeable dideoxyuridine 5'-monophosphate analogue inhibits human immunodeficiency virus infection.
Molecular pharmacology 1992;41(3):441-5.
1992: Varsha Gandhi; A Kemena; Michael J Keating; William Plunkett
Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Cancer research 1992;52(4):897-903.
1992: P Huang; D Farquhar; William Plunkett
Selective action of 2',3'-didehydro-2',3'-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases.
The Journal of biological chemistry 1992;267(4):2817-22.
1992: S W Yang; P Huang; William Plunkett; Frederick F Becker; J Y Chan
Dual mode of inhibition of purified DNA ligase I from human cells by 9-beta-D-arabinofuranosyl-2-fluoroadenine triphosphate.
The Journal of biological chemistry 1992;267(4):2345-9.
1992: V Heinemann; Y Z Xu; S Chubb; A Sen; L W Hertel; G B Grindey; William Plunkett
Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
Cancer research 1992;52(3):533-9.
1992: Michael J Keating; Elihu Estey; Andrew Lamb; William Plunkett; Susan O'Brien; Charles Koller; Miloslav Beran; Emil J Freireich
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Leukemia 1992;6 Suppl 2():78-80.
1992: A Kemena; Varsha Gandhi; Donna S Shewach; Michael Keating; William Plunkett
Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
Cancer chemotherapy and pharmacology 1992;31(3):193-9.
1992: Varsha Gandhi; William Plunkett
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
Cancer chemotherapy and pharmacology 1992;31(1):11-7.
1991: P Huang; S Chubb; L W Hertel; G B Grindey; William Plunkett
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Cancer research 1991;51(22):6110-7.
1991: A Kemena; M Fernandez; J Bauman; Michael Keating; William Plunkett
A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids.
Clinica chimica acta; international journal of clinical chemistry 1991;200(2-3):95-106.
1991: P Huang; William Plunkett
Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism.
Molecular pharmacology 1991;39(4):449-55.
1991: R Grunewald; James L Abbruzzese; P Tarassoff; William Plunkett
Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
Cancer chemotherapy and pharmacology 1991;27(4):258-62.
1991: Varsha Gandhi; P Huang; Y Z Xu; V Heinemann; William Plunkett
Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity.
Advances in experimental medicine and biology 1991;309A():125-30.
1991: William Plunkett; P P Saunders
Metabolism and action of purine nucleoside analogs.
Pharmacology & therapeutics 1991;49(3):239-68.
1990: R Grunewald; Andrew Lamb; Michael J Keating; James L Abbruzzese; P Tarassoff; William Plunkett
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
Cancer research 1990;50(21):6823-6.
1990: V Heinemann; Y Z Xu; S Chubb; A Sen; L W Hertel; G B Grindey; William Plunkett
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
Molecular pharmacology 1990;38(4):567-72.
1990: William Plunkett; P Huang; Varsha Gandhi
Metabolism and action of fludarabine phosphate.
Seminars in oncology 1990;17(5 Suppl 8):3-17.
1990: P Huang; S Chubb; William Plunkett
Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity.
The Journal of biological chemistry 1990;265(27):16617-25.
1990: P Huang; D Farquhar; William Plunkett
Selective action of 3'-azido-3'-deoxythymidine 5'-triphosphate on viral reverse transcriptases and human DNA polymerases.
The Journal of biological chemistry 1990;265(20):11914-8.
1990: Varsha Gandhi; William Plunkett
Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides.
Cancer research 1990;50(12):3675-80.
1990: Elihu H Estey; Michael J Keating; K B McCredie; Emil J Freireich; William Plunkett
Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
Leukemia 1990;4(2):95-9.
1990: William Plunkett; V Heinemann; Elihu Estey; Michael Keating
Pharmacologically directed design of leukemia therapy.
Haematology and blood transfusion 1990;33():610-3.
1990: Michael J Keating; H Kantarjian; Elihu Estey; William Plunkett; J Trujillo; K B McCredie
Karyotype of leukemia cells consistently predicts for response to therapy and survival following salvage therapy in acute myeloblastic leukemia.
Haematology and blood transfusion 1990;33():593-603.
1989: V Heinemann; William Plunkett
Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine.
Biochemical pharmacology 1989;38(22):4115-21.
1989: Varsha Gandhi; B Nowak; Michael J Keating; William Plunkett
Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy.
Blood 1989;74(6):2070-5.
1989: Varsha Gandhi; William Plunkett
Interaction of arabinosyl nucleotides in K562 human leukemia cells.
Biochemical pharmacology 1989;38(20):3551-8.
1989: Michael J Keating; Andrew Lamb; Moshe Talpaz; J Redman; Charles Koller; Bart Barlogie; W Velasquez; William Plunkett; Emil J Freireich; K B McCredie
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
Blood 1989;74(1):19-25.
1989: V Heinemann; Elihu Estey; Michael J Keating; William Plunkett
Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(5):622-8.
1988: V Heinemann; L W Hertel; G B Grindey; William Plunkett
Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
Cancer research 1988;48(14):4024-31.
1988: Varsha Gandhi; William Plunkett
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
Cancer research 1988;48(2):329-34.
1988: V Heinemann; D Murray; R Walters; R E Meyn; William Plunkett
Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine.
Cancer chemotherapy and pharmacology 1988;22(3):205-10.
1987: L Danhauser; William Plunkett; J Liliemark; Varsha Gandhi; S Iacoboni; Michael Keating
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Leukemia 1987;1(9):638-43.
1987: Elihu Estey; William Plunkett; D Dixon; Michael Keating; K McCredie; Emil J Freireich
Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia.
Leukemia 1987;1(8):580-3.
1987: Varsha Gandhi; L Danhauser; William Plunkett
Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography.
Journal of chromatography 1987;413():293-9.
1987: William Plunkett; G B Grindey
Pharmacokinetics of the 5'-triphosphates of arabinosylcytosine and 2',2'-difluorodeoxycytidine in L1210 cells.
Nucleic acids symposium series 1987;(18):77-9.
1986: P P Saunders; M T Tan; C D Spindler; R K Robins; William Plunkett
3-Deazaguanosine is metabolized to the triphosphate derivative in Chinese hamster cells deficient in hypoxanthine-guanine phosphoribosyltransferase.
The Journal of biological chemistry 1986;261(14):6416-22.
1985: William Plunkett; S Iacoboni; E Estey; L Danhauser; J O Liliemark; M J Keating
Pharmacologically directed ara-C therapy for refractory leukemia.
Seminars in oncology 1985;12(2 Suppl 3):20-30.